###begin article-title 0
###xml 106 110 106 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 42 49 <span type="species:ncbi:9606">patient</span>
Three synchronous primary carcinomas in a patient with HNPCC associated with a novel germline mutation in MLH1: Case report
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
MLH1 is one of six known genes responsible for DNA mismatch repair (MMR), whose inactivation leads to HNPCC. It is important to develop genotype-phenotype correlations for HNPCC, as is being done for other hereditary cancer syndromes, in order to guide surveillance and treatment strategies in the future.
###end p 2
###begin title 3
Case presentation
###end title 3
###begin p 4
###xml 129 133 129 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 390 395 390 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 424 428 424 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 140 147 <span type="species:ncbi:9606">patient</span>
We report a 47 year-old male with hereditary nonpolyposis colorectal cancer (HNPCC) associated with a novel germline mutation in MLH1. This patient expressed a rare and severe phenotype characterized by three synchronous primary carcinomas: ascending and splenic flexure colon adenocarcinomas, and ureteral carcinoma. Ureteral neoplasms in HNPCC are most often associated with mutations in MSH2 and rarely with mutations in MLH1. The reported mutation is a two base pair insertion into exon 10 (c.866_867insCA), which results in a premature stop codon.
###end p 4
###begin title 5
Conclusion
###end title 5
###begin p 6
###xml 47 52 47 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 33 41 <span type="species:ncbi:9606">patients</span>
Our case demonstrates that HNPCC patients with MLH1 mutations are also at risk for ureteral neoplasms, and therefore urological surveillance is essential. This case adds to the growing list of disease-causing MMR mutations, and contributes to the development of genotype-phenotype correlations essential for assessing individual cancer risk and tailoring of optimal surveillance strategies. Additionally, our case draws attention to limitations of the Amsterdam Criteria and the need to maintain a high index of suspicion when newly diagnosed colorectal cancer meets the Bethesda Criteria. Establishment of the diagnosis is the crucial first step in initiating appropriate surveillance for colorectal cancer and other HNPCC-associated tumors in at-risk individuals.
###end p 6
###begin title 7
Background
###end title 7
###begin p 8
###xml 208 209 208 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 325 326 325 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 547 548 547 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 609 614 609 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 632 637 632 637 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 697 701 697 701 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6</italic>
###xml 703 707 703 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PMS1</italic>
###xml 709 713 709 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PMS2</italic>
###xml 719 724 719 724 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH3 </italic>
###xml 725 726 725 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 882 883 882 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 884 885 884 885 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
Colorectal cancer (CRC) is currently the third leading cause of cancer and cancer-related deaths in the United States, estimated to be responsible for 10% of new cancer cases and 9% of cancer deaths in 2008 [1]. Hereditary nonpolyposis colorectal cancer (HNPCC), or Lynch syndrome, is the most common heritable CRC syndrome [2], accounting for approximately 5% of all CRC cases. Transmitted in an autosomal dominant fashion, HNPCC is associated with tumorigenesis caused by mutations in one of several genes involved in DNA mismatch repair (MMR) [3]. About 90% of HNPCC cases are associated with mutations in MLH1 (OMIM #120436) or MSH2 (OMIM #609309), and others are associated with mutations in MSH6, PMS1, PMS2, and MLH3 [4]. Reported MMR mutations have been catalogued in three online databases that document the full spectrum of mutations and phenotypes associated with HNPCC [5-7].
###end p 8
###begin p 9
###xml 162 163 162 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 310 311 310 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 458 460 458 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 540 542 540 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 543 545 543 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 759 761 759 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 590 598 <span type="species:ncbi:9606">patients</span>
In HNPCC, as in various other cancer syndromes, a somatic mutation or epigenetic event is needed as the "second hit" to disable the functional, wild-type allele [8]. Abolition of MMR raises the basal rate of mutation and leads to microsatellite instability (MSI), a tissue marker of defective mismatch repair [9]. This increased level of mutagenesis is most likely to affect tissues that undergo a high rate of cell division, such as the colonic epithelium [10]. Carriers of MMR mutations have up to an 82% lifetime risk of developing CRC [11,12]. Aside from demonstrating an MMR mutation, patients may be clinically diagnosed with HNPCC if their family cancer history meets the Amsterdam Criteria II, which encompasses CRC and associated extracolonic sites [13].
###end p 9
###begin p 10
###xml 212 214 212 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 420 422 420 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 423 425 423 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 718 722 718 722 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 180 185 <span type="species:ncbi:9606">women</span>
###xml 253 261 <span type="species:ncbi:9606">patients</span>
###xml 464 467 <span type="species:ncbi:9606">man</span>
HNPCC also carries the risk of developing cancer at various other sites. The most clinically significant extracolonic cancer associated with HNPCC is endometrial cancer, for which women have a 60% lifetime risk [11]. Compared to the general population, patients with HNPCC are 14-fold more likely to develop urothelial cell carcinoma of the upper urinary tract, corresponding to a cumulative lifetime risk of 2.6%-4.0% [11,14]. We report the case of a 47-year old man with a rare presentation of two distinct colorectal adenocarcinomas and a synchronous ureteral neoplasm. A definitive diagnosis of HNPCC was only established post-operatively following identification of a not previously reported germline mutation in MLH1.
###end p 10
###begin title 11
Case presentation
###end title 11
###begin p 12
###xml 14 17 <span type="species:ncbi:9606">man</span>
A 47-year old man of Puerto Rican descent presented with recent gross hematuria and a history of lower abdominal pain of 1-2 years duration. Other comorbidities included hypertension and Type II diabetes mellitus. He had a 20-year history of heavy smoking. Colonoscopy three years prior to presentation revealed no evidence of adenomatous polyps or colorectal cancer.
###end p 12
###begin p 13
###xml 205 207 205 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1a</xref>
###xml 440 445 440 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1a, b</xref>
Urine cytology revealed the presence of numerous red blood cells, as well as atypical urothelial cells. A subsequent CT scan revealed a mass in the mid-right ureter suggestive of a ureteral neoplasm (Fig. 1a). A ureteroscopic biopsy revealed urothelial mucosa with papillary architecture, suspicious for invasive urothelial cell carcinoma. Subsequent colonoscopy revealed synchronous tumors in the ascending colon and splenic flexure (Fig. 1a, b), and biopsies confirmed both lesions were adenocarcinomas. A two-centimeter flat lesion was also identified in the transverse colon, and biopsy was consistent with a flat adenoma with focal high-grade dysplasia.
###end p 13
###begin p 14
###xml 0 86 0 86 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(a) CT scan with PO/IV contrast suggested a large tumor of the ascending colon (arrow)</bold>
(a) CT scan with PO/IV contrast suggested a large tumor of the ascending colon (arrow). Enlarged pericolic lymph nodes are suggestive of metastases. Also shown is right-sided hydroureteronephrosis caused by the mid-ureteral tumor (arrowhead). (b) The colon tumor at the splenic flexure tumor is visible on a different cut (arrow).
###end p 14
###begin p 15
###xml 64 71 <span type="species:ncbi:9606">patient</span>
###xml 285 292 <span type="species:ncbi:9606">patient</span>
The three tumors were resected in a combined operation, and the patient recovered from surgery without complication. The urothelial cell carcinoma was high-grade, pT3 N2 Mx, Stage IV, and the more advanced colon adenocarcinoma was moderately differentiated, pT3 N1 Mx, Stage IIIB. The patient received adjuvant chemotherapy consisting of cisplatin and taxol combined with radiotherapy, and is disease-free at the time of publication.
###end p 15
###begin p 16
###xml 83 84 83 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2</xref>
###xml 91 98 <span type="species:ncbi:9606">patient</span>
###xml 239 246 <span type="species:ncbi:9606">patient</span>
A comprehensive family history was taken and a formal pedigree was assembled (Fig. 2). The patient's father died of colon cancer shortly after diagnosis at age 55, and three other paternal family members had cancer in an unknown site. The patient's paternal grandmother died at an early age of unknown causes. Four maternal family members had cancer in unconfirmed sites, and one had acute lymphoblastic leukemia.
###end p 16
###begin p 17
###xml 0 46 0 46 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">The patient (proband) is indicated by an arrow</bold>
###xml 4 11 <span type="species:ncbi:9606">patient</span>
The patient (proband) is indicated by an arrow. Age of diagnosis or death is indicated if known. Diamonds indicate a group of siblings of unknown sex. Solid boxes indicate a diagnosis of colon cancer, and crosshatched boxes indicate cancer of non-colorectal origin. A diagonal strikethrough indicates a deceased individual. Unconfirmed diagnoses of individuals with extracolonic cancer are noted. Unaffected members of the extended family have been omitted for conciseness. One family member died in childhood from acute lymphoblastic leukemia (ALL).
###end p 17
###begin p 18
###xml 176 178 176 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 314 315 314 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">3</xref>
###xml 352 356 352 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 484 485 484 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">3</xref>
###xml 13 20 <span type="species:ncbi:9606">patient</span>
###xml 505 512 <span type="species:ncbi:9606">patient</span>
Although the patient's family history did not satisfy Amsterdam Criteria II, the early age-of-onset and presence of synchronous tumors fulfilled the Revised Bethesda Criteria [15]. Immunohistochemistry (IHC) on surgical specimens was as follows: MLH1 stained negative and MSH2 stained positive in all tumors (Fig. 3), strongly suggesting a mutation in MLH1. Differential staining for cytokeratins 7 and 20 confirmed distinct histological origin of the ureteral and colon tumors (Fig. 3). Accordingly, the patient was referred for genetic counseling and germline mutation testing.
###end p 18
###begin p 19
###xml 0 99 0 99 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Three immunohistochemical stains (40&#215;) from the patient's ureteral tumor and a selected colon tumor</bold>
###xml 48 55 <span type="species:ncbi:9606">patient</span>
Three immunohistochemical stains (40x) from the patient's ureteral tumor and a selected colon tumor. The colon and ureteral cancers stained negative for MLH1 and positive for MSH2. Both colon tumors stained negative for cytokeratin 7 and positive for cytokeratin 20, whereas the ureteral tumor stained positive for both cytokeratins, demonstrating a distinct organ of origin for each tumor type and thus discounting the possibility that either tumor type is a metastasis of the other. Data not shown for positive controls.
###end p 19
###begin p 20
###xml 98 103 98 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 132 133 132 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">4</xref>
PCR amplification and sequencing on a peripheral blood sample identified the novel c.866_867insCA MLH1 insertion into exon 10 (Fig. 4). This frameshift mutation is predicted to produce a truncated, nonfunctional protein product due to a premature stop codon within exon 10 at amino acid residue 297. Review of the available databases revealed this specific mutation had not been previously reported.
###end p 20
###begin p 21
###xml 38 43 38 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 0 72 0 72 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sequence data pertaining to the novel <italic>MLH1 </italic>mutation found in the proband</bold>
Sequence data pertaining to the novel MLH1 mutation found in the proband. A two-nucleotide 5'-CA-3' insertion (box) between base pair positions 866 and 867 leads to nonsense coding of amino acid residues and predicted truncation of the protein product (c.866_867insCA). Note: due to the palindromic nature of the insertion site, the insertion may also be classified as a 5'-AC-3' insertion between base pairs 867 and 868.
###end p 21
###begin title 22
Discussion
###end title 22
###begin p 23
###xml 126 127 126 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
There are at least 2200 total variants in the six known MMR genes, with at least 323 of these reported to be disease-causing [6]. However, unlike familial adenomatous polyposis, very little is known about phenotypic variation as a function of the MMR gene involved or the location and nature of the specific MMR gene mutation. Hence, it is important to report novel MMR mutations in order to develop genotype-phenotype correlations and add to the mutation databases that serve as a reference for genetic diagnosis.
###end p 23
###begin p 24
###xml 75 80 75 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 315 323 315 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo </italic>
###xml 26 33 <span type="species:ncbi:9606">patient</span>
###xml 232 239 <span type="species:ncbi:9606">patient</span>
###xml 384 391 <span type="species:ncbi:9606">patient</span>
The history of CRC in the patient's father suggests paternal origin of the MLH1 mutation. However, the origin of this mutation cannot be definitively determined, given that affected paternal family members are deceased and that the patient's mother declined genetic testing. Furthermore, it remains possible that a de novo mutation may have occurred in the proband. Nevertheless, the patient's at-risk siblings have been advised to undergo colonoscopy, evaluation of the upper urinary tracts and to seek genetic counseling.
###end p 24
###begin p 25
###xml 151 153 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 1230 1232 1230 1232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 80 88 <span type="species:ncbi:9606">patients</span>
###xml 161 168 <span type="species:ncbi:9606">patient</span>
###xml 389 396 <span type="species:ncbi:9606">patient</span>
###xml 860 867 <span type="species:ncbi:9606">patient</span>
###xml 935 942 <span type="species:ncbi:9606">patient</span>
###xml 1018 1026 <span type="species:ncbi:9606">patients</span>
###xml 1421 1429 <span type="species:ncbi:9606">patients</span>
The American Cancer Society (ACS) recommends annual or biennial colonoscopy for patients diagnosed with HNPCC by clinical criteria or genetic testing [16]. This patient's family history did not fulfill Amsterdam Criteria, and he was therefore not categorized as having HNPCC, but rather as having increased risk for CRC given a first-degree relative affected by CRC at age < 60. Thus, the patient followed the appropriate ACS screening guidelines: colonoscopy every 5 years starting at age 40. Although the revised criteria (Amsterdam Criteria II) are very specific and more sensitive than the original Amsterdam Criteria, there are still a substantial number of mutation-positive cases in which the family cancer history does not satisfy either set of Amsterdam Criteria. Limitations to obtaining an accurate family history include unavailability of original patient records, unrecognized infidelity within the family, and inaccurate patient recall. Indeed, a recent prospective population-based study found that CRC patients being evaluated for HNPCC using the Amsterdam Criteria were considerably inaccurate when recalling malignancies of family members: false-negative and false-positive rates were 39% and 21%, respectively [17]. This case illustrates the consequences of failing to recognize a hereditary CRC syndrome, despite following appropriate surveillance guidelines. Thus, recognition of newly diagnosed CRC patients that meet Bethesda Criteria should lead to evaluation with IHC and MSI testing of the tumor, as well as possible germline testing, despite a family history that does not satisfy Amsterdam Criteria. If a diagnosis of HNPCC is established, at-risk family members can be offered genetic testing and begin appropriate surveillance for HNPCC-associated tumors.
###end p 25
###begin p 26
###xml 101 103 101 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 104 106 104 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 107 109 107 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 158 163 158 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 290 295 290 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 377 379 377 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 486 491 486 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 502 504 502 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 573 578 573 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 615 620 615 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 631 633 631 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 736 741 736 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 844 849 844 849 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 899 901 899 901 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 6 14 <span type="species:ncbi:9606">patients</span>
###xml 144 152 <span type="species:ncbi:9606">patients</span>
###xml 276 284 <span type="species:ncbi:9606">patients</span>
###xml 451 459 <span type="species:ncbi:9606">patients</span>
###xml 722 730 <span type="species:ncbi:9606">patients</span>
HNPCC patients have an elevated lifetime risk (approximately 3-4%) of upper urinary tract carcinoma [11,14,18]. A recent Dutch study found that patients with MSH2 mutations have a significantly higher risk of upper urinary tract cancer (12% by age 70, P = < 0.05) compared to patients with MLH1 mutations, who did not have an increased risk compared to the general population [19]. Similarly, a British study reported 13 ureteral cancers in 130 HNPCC patients; all were associated with MSH2 mutations [20]. In a Danish study, 11 of 12 ureteral cancers were attributable to MSH2 mutations (one was associated with a MLH1 mutation) [21]. Taken together, these studies suggest that the risk of ureteral cancer is elevated in patients with MSH2 mutations. Our case highlights the fact that ureteral cancer is also possible in individuals harboring MLH1 mutations. Others have reported similar findings [18]. Further study is necessary to determine whether surveillance recommendations for urinary tract cancer in HNPCC should be stratified by the MMR gene involved.
###end p 26
###begin p 27
###xml 244 246 244 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 371 373 371 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 374 376 374 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 408 410 408 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 622 624 622 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 433 440 <span type="species:ncbi:9606">patient</span>
###xml 451 459 <span type="species:ncbi:9606">patients</span>
Specific histological characteristics have been found for urothelial cell carcinomas associated with HNPCC. Papillary architecture in urothelial cell carcinoma has a sensitivity and specificity of 70% and 78%, respectively, for predicting MSI [22]. Furthermore, IHC staining detects the loss of an MMR protein in 78-87% of upper urothelial cancers with demonstrated MSI [23,24], most commonly MSH2 and MSH6 [25]. Consistent with our patient, in HNPCC patients with upper tract urothelial cancers staining negative for at least one MMR protein, extracolonic tumors nearly always demonstrated the same MMR staining profile [25].
###end p 27
###begin p 28
###xml 301 303 301 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 663 665 663 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 904 906 904 906 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 1089 1091 1089 1091 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 151 159 <span type="species:ncbi:9606">patients</span>
###xml 435 443 <span type="species:ncbi:9606">patients</span>
Unfortunately, a satisfactory screening test for ureteral cancer does not currently exist. Although annual urine cytology is generally recommended for patients with HNPCC, this test was recently found to have indeterminate sensitivity (29%) for detecting urinary tract cancer in the setting of HNPCC [21]. In HNPCC kindreds with a history of ureteral cancer or high-risk mutations, more aggressive screening may be indicated. In these patients, routine urinalysis and cytology may be combined with more contemporary methods of evaluating the upper urinary tract including cystoscopy-ureteroscopy, intravenous pyelography, ultrasonography, and CT or MR urography [14]. If suspicion of malignancy remains after cytology and imaging, FISH (fluorescence in situ-hybridization) assays may be useful: they can detect upper urothelial cell carcinomas with a sensitivity of 33% for Grade 1 and 100% for Grade 2 [26]. The two newly-approved commercial FISH assays promise to offer vast improvements over traditional cytology for detection of upper and lower urinary tract carcinomas of all grades [26].
###end p 28
###begin title 29
Conclusion
###end title 29
###begin p 30
###xml 3 11 <span type="species:ncbi:9606">patients</span>
###xml 233 241 <span type="species:ncbi:9606">Patients</span>
###xml 449 457 <span type="species:ncbi:9606">patients</span>
In patients with a family history characterized by multiple cases of CRC or extracolonic HNPCC-associated tumors, the possibility of HNPCC must be considered so that appropriate surveillance of at-risk individuals can be instituted. Patients presenting with ureteral cancer, particularly when MSI or suggestive histology is present, should be referred for colonoscopy as well as genetic risk assessment and possible germline testing. Conversely, in patients with known HNPCC, ureteral cancer surveillance is essential. Urine cytology alone appears to be ineffective; accuracy may be improved with the addition of cross-sectional imaging, ureteroscopic evaluation and FISH analysis. Reporting of novel disease-causing mutations, including information about ethnicity, is important for establishing genotype-phenotype correlations. It is anticipated that well-defined genotype-phenotype correlations will facilitate tailoring of surveillance strategies in the future.
###end p 30
###begin title 31
Consent
###end title 31
###begin p 32
###xml 47 54 <span type="species:ncbi:9606">patient</span>
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
###end p 32
###begin title 33
Competing interests
###end title 33
###begin p 34
The authors have no commercial or financial associations that might create a conflict of interest with the information presented in this manuscript.
###end p 34
###begin title 35
Authors' contributions
###end title 35
###begin p 36
###xml 0 3 <span type="species:ncbi:11232?0.9015317286652079">CDV</span>
###xml 284 291 <span type="species:ncbi:9606">patient</span>
###xml 424 427 <span type="species:ncbi:11232?0.9015317286652079">CDV</span>
CDV analyzed the data and wrote the first draft of the manuscript. HGM and HLP are attending surgeons who conceived the case report. WCH is the attending urologist who researched urologic tumors in HNPCC. EWR is the genetic counselor and HO is the medical geneticist who analyzed the patient's pedigree along with genetic sequencing data. HY is the attending pathologist who collected and prepared the histological figures. CDV, HGM, WCH, EWR, HY, HO, and HLP have been involved in drafting the manuscript and revising it critically for important intellectual content. All authors have read and approved the final manuscript.
###end p 36
###begin title 37
Acknowledgements
###end title 37
###begin p 38
The authors thank Mark S. Hochberg for guidance and support, Mei X. Peng for technical assistance, and Melinda Kwan for advice on disease prevalence.
###end p 38
###begin article-title 39
Cancer statistics, 2008
###end article-title 39
###begin article-title 40
###xml 41 49 <span type="species:ncbi:9606">patients</span>
Practice parameters for the treatment of patients with dominantly inherited colorectal cancer (familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer)
###end article-title 40
###begin article-title 41
Hereditary colorectal cancer and polyposis syndromes
###end article-title 41
###begin article-title 42
Hereditary colorectal cancer
###end article-title 42
###begin article-title 43
A new variant database for mismatch repair genes associated with Lynch syndrome
###end article-title 43
###begin article-title 44
InSiGHT: International Society for Gastrointestinal Hereditary Tumors, Mismatch Repair Mutation Database
###end article-title 44
###begin article-title 45
MMR Gene Unclassified Variants Database
###end article-title 45
###begin article-title 46
Evidence for the role of aberrant DNA methylation in the pathogenesis of Lynch syndrome adenomas
###end article-title 46
###begin article-title 47
Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer
###end article-title 47
###begin article-title 48
Self-renewal and cancer of the gut: Two sides of a coin
###end article-title 48
###begin article-title 49
Cancer risk in mutation carriers of DNA-mismatch-repair genes
###end article-title 49
###begin article-title 50
Colorectal cancer in HNPCC: Cumulative lifetime incidence, survival and tumour distribution. A report of 121 families with proven mutations
###end article-title 50
###begin article-title 51
New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC
###end article-title 51
###begin article-title 52
Urinary tract cancer and hereditary nonpolyposis colorectal cancer: Risks and screening options
###end article-title 52
###begin article-title 53
###xml 36 44 <span type="species:ncbi:9606">patients</span>
Identification in daily practice of patients with Lynch syndrome (hereditary nonpolyposis colorectal cancer): Revised Bethesda guidelines-based approach versus molecular screening
###end article-title 53
###begin article-title 54
Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: A joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology
###end article-title 54
###begin article-title 55
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient accuracy of reporting on hereditary non-polyposis colorectal cancer-related malignancy in family members
###end article-title 55
###begin article-title 56
Differential cancer predisposition in Lynch syndrome: Insights from molecular analysis of brain and urinary tract tumors
###end article-title 56
###begin article-title 57
MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: A study of hereditary nonpolyposis colorectal cancer families
###end article-title 57
###begin article-title 58
Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC)
###end article-title 58
###begin article-title 59
Screening for urinary tract cancer with urine cytology in Lynch syndrome and familial colorectal cancer
###end article-title 59
###begin article-title 60
Urothelial carcinoma of the upper urinary tract: Inverted growth pattern is predictive of microsatellite instability
###end article-title 60
###begin article-title 61
Frequent microsatellite instability in sporadic tumors of the upper urinary tract
###end article-title 61
###begin article-title 62
Distinct patterns of microsatellite instability are seen in tumours of the urinary tract
###end article-title 62
###begin article-title 63
Low frequency of defective mismatch repair in a population-based series of upper urothelial carcinoma
###end article-title 63
###begin article-title 64
Diagnosis of urothelial carcinoma from urine
###end article-title 64

